Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer

Annals of Surgery

Volumn 260, Issue 5, 2014, Pages 807-814

  Shapiro, Joel ^a   Van Hagen, Pieter ^a   Lingsma, Hester F ^a   Wijnhoven, Bas P L ^a   Biermann, Katharina ^a   Ten Kate, Fiebo J W ^a   Steyerberg, Ewout W ^a   Van Der Gaast, Ate ^a   Van Lanschot, J Jan B ^a   Hulshof, Maarten C C M ^b   Van Berge Henegouwen, Mark I ^b   Van Laarhoven, Hanneke W M ^b   Nieuwenhuijzen, Grard A P ^c   Hospers, Geke A P ^d   Bonenkamp, Johannes J ^e   Cuesta, Miguel A ^f   Blaisse, Reinoud J B ^g   Busch, Olivier R C ^g   Creemers, Geert Jan ^c   Punt, Cornelis J A ^b   Plukker, John T M ^d   Verheul, Henk M W ^f   Bilgen, Ernst J Spillenaar ^g   Van Dekken, Herman ^a   Van Der Sangen, Maurice J C ^c   Rozema, Tom ^e   Beukema, Jannet C ^d   Piet, Anna H M ^f   Van Rij, Caroline M ^a   Reinders, Janny G ^h   Tilanus, Hugo W ^a   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c CATHARINA HOSPITAL   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g RIJNSTATE HOSPITAL   (Netherlands)

^h Radiotherapeutic Institute   (Netherlands)

Author keywords

Esophageal cancer; Esophagogastric junctional cancer; Neoadjuvant chemoradiotherapy; Pathologically complete response; Postoperative complications; Surgery; Timing of surgery

Indexed keywords

ADENOCARCINOMA; ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; CANCER GROWTH; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONFERENCE PAPER; DISEASE FREE SURVIVAL; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; JUNCTIONAL CANCER; KARNOFSKY PERFORMANCE STATUS; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OPERATIVE BLOOD LOSS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROLONGED TIME TO SURGERY; TIME TO TREATMENT; WEIGHT REDUCTION; ADJUVANT THERAPY; CHEMORADIOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGEAL NEOPLASMS; ESOPHAGUS RESECTION; LOWER ESOPHAGUS SPHINCTER; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TIME;

ANTINEOPLASTIC AGENT;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; POSTOPERATIVE COMPLICATIONS; SURVIVAL RATE; TIME FACTORS;

EID: 84923478650     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000966     Document Type: Conference Paper

References (41)

1. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: An updated meta-analysis. Lancet Oncol. 2011;12:681-692.
2. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366: 2074-2084.
3. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations. Cancer. 1994;73:2680-2686.
4. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347-1355.
5. Schneider PM, Baldus SE, Metzger R, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242:684-692.
6. Donohoe CL, O'Farrell NJ, Grant T, et al. Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: Assessment of existing measures and proposal of a novel 3-point standard. Ann Surg. 2013;258:784-792.
7. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long-term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer. 2001;91:2165-7214.
8. Reynolds JV, Muldoon C, Hollywood D, et al. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg. 2007;245:707-716.
9. Verlato G, Zanoni A, Tomezzoli A, et al. Response to induction therapy in oesophageal and cardia carcinoma using Mandard tumour regression grade or size of residual foci. Br J Surg. 2010;97:719-725.
10. Vallböhmer D, Hölscher AH, DeMeester S, et al. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer. Ann Surg. 2010;252:744-749.
11. Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R90-01 randomized trial. J Clin Oncol. 1999;17:2396-2402.
12. Dolinsky CM, Mahmoud NN, Mick R, et al. Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer. J Surg Oncol. 2007;96:207-212.
13. Tulchinsky H, Shmueli E, Figer A, et al. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and diseasefree survival in patients with locally advanced rectal cancer. Ann Surg Oncol. 2008;15:2661-2667.
14. Kalady MF, de Campos-Lobato LF, Stocchi L, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg. 2009;250:582-589.
15. de Campos-Lobato LF, Geisler DP, da Luz Moreira A, et al. Neoadjuvant therapy for rectal cancer: The impact of longer interval between chemoradiation and surgery. J Gastrointest Surg. 2010;15:444-450.
16. Wolthuis AM, Penninckx F, Haustermans K, et al. Impact of interval between neoadjuvant chemoradiotherapy and TMEfor locally advanced rectal cancer on pathologic response and oncologic outcome. Ann Surg Oncol. 2012;19:2833- 2841.
17. Sloothaak DA, Geijsen DE, van Leersum NJ, et al. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg. 2013;100:933-939.
18. Petrelli F, Sgroi G, Sarti E, et al. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: A meta-analysis of published studies. Ann Surg. November 20, 2013 [Epub ahead of print].
19. Moore HG, Gittleman AE, Minsky BD, et al. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum. 2004;47: 279-286.
20. Habr-Gama A, Perez RO, Proscurshim I, et al. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome? Int J Radiat Oncol Biol Phys. 2008;71:1181-1188.
21. Kerr SF, Norton S, Glynne-Jones R. Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis. Br J Surg. 2008;95:1534-1540.
22. Lim SB, Choi HS, Jeong SY, et al. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers. Ann Surg. 2008;248:243-251.
23. Ruol A, Rizzetto C, Castoro C, et al. Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome? Ann Surg. 2010;252: 788-796.
24. Kim JY, Correa AM, Vaporciyan AA, et al. Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg. 2012;93: 207-213.
25. Van Meerten E, MullerK, Tilanus HW, et al. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: A phase II study. Br J Cancer. 2006;94:1389-1394.
26. van Meerten E, van der Gaast A, Tilanus HW, et al. Pathological analysis after neoadjuvant chemoradiotherapy for esophageal carcinoma: The Rotterdam experience. J Surg Oncol. 2009;100:32-37.
27. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-213.
28. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250: 187-196.
29. Charlson ME, Pompei P, Ales KL, et al.Anewmethod of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
30. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeodCM, ed. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949:191-205.
31. Mor V, Laliberte L, Morris JN, et al. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer. 1984;53:2002-2007.
32. Harrell FE Jr, Lee KL, Pollock BG. Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer Inst. 1988;80:1198-1202.
33. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711-718.
34. Habr-Gama A, Perez RO. Non-operative management of rectal cancer after neoadjuvant chemoradiation. Br J Surg. 2009;96:125-127.
35. Maas M, Beets-Tan RG, Lambregts DM, et al.Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29:4633-4640.
36. Bokkerink GM, de Graaf EJ, Punt CJ, et al. The CARTS study: Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery. BMC Surg. 2011;11:34.
37. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. Lancet Oncol. 2007;8:797-805.
38. Schneider PM, Metzger R, Schaefer H, et al. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg. 2008;248:902-908.
39. Vallböhmer D, Hölscher AH, Dietlein M, et al. [18F]-Fluorodeoxyglucosepositron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg. 2009;250:888-894.
40. Van Heijl M, Omloo JM, van Berge Henegouwen MI, et al. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg. 2011;253:56-63.
41. Shapiro J, ten Kate FJ, van Hagen P, et al. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa. Ann Surg. 2013;258:678-688.